SCHEMBL12929971

SCHEMBL12929971

CCCc1ccc(C(C)C)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ CALM1 P0DP23 1/20 0.44
▸ STAT3 P40763 1/20 0.42
▸ ALOX5 P09917 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ CYP19A1 P11511 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12961032 0.86 ATM (0.42) ATMKDM4ECALM1STAT3ALOX5
SCHEMBL12806458 0.85 PTGS2 (0.48) ATMKDM4ECALM1POLBCYP1A2
SCHEMBL13547951 0.81 FOS (0.40) ATMKDM4EPOLBCYP19A1ALDH1A1
SCHEMBL30842461 0.80 TTR (0.50) ATMKDM4EPOLBALDH1A1CA2
SCHEMBL17540838 0.80 KDM4E (0.46) ATMKDM4EPOLBCYP19A1TSHR
SCHEMBL30842447 0.80 THRB (0.48) STAT3POLBCYP3A4NPC1RAB9A
SCHEMBL13548297 0.80 FOS (0.50) GABRA1GABRB2POLBCYP3A4CA2
SCHEMBL16953889 0.80 THRB (0.48) STAT3POLBCYP3A4NPC1RAB9A
SCHEMBL8233467 0.80 CA2 (0.42) ATMKDM4ESTAT3POLBCYP3A4
SCHEMBL427541 0.79 ATM (0.68) ATMKDM4ESTAT3POLBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344138-B2 Triazinedione derivatives as GABAB receptor modulators ADDEX PHARMA S.A. (CH) 2013-01-01 — — US disclosed
US-20110015401-A1 Metal-Catalyzed Carbon-Fluorine Bond Formation MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-01-20 — — US disclosed
US-20100004246-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS ADDEX PHARMA SA (CH) 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004246-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS CHRNA5, GABRA5, GABRB3 ATM 3449/4885KDM4E 2122/4885CALM1 562/4885
US-20110015401-A1 Metal-Catalyzed Carbon-Fluorine Bond Formation FLI1, VGF, GMFG ATM 1893/4885KDM4E 982/4885CALM1 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback